Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bafna PharmaceuticalsNSE:BAFNAPH -2.00%60 EV-to-EBITDA is 29.62 as of Jul. 26, 2026, which is 81% above its 10-year median of 16.33. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 60/100 and a GF Value™ of ₹91.24 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 742 Drug Manufacturers companies, Bafna Pharmaceuticals ranks worse than 80.86% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bafna Pharmaceuticals's enterprise value is ₹6,133 Mil.
Bafna Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹207 Mil. Therefore, Bafna Pharmaceuticals's EV-to-EBITDA for today is 29.62.
The historical rank and industry rank for Bafna Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
NSE:BAFNAPH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.33 Med: 16.33 Max: 234.33
Current: 29.62
During the past 13 years, the highest EV-to-EBITDA of Bafna Pharmaceuticals was 234.33. The lowest was -7.33. And the median was 16.33.
NSE:BAFNAPH's EV-to-EBITDA is ranked worse than 80.86% of 742
companies
in the Drug Manufacturers industry
Industry Median: 12.98
vs NSE:BAFNAPH: 29.62
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bafna Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Bafna Pharmaceuticals's share price for today is ₹238.15.
Bafna Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4.690.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Bafna Pharmaceuticals EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Bafna Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bafna Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bafna Pharmaceuticals's EV-to-EBITDA falls into.
Bafna Pharmaceuticals's current Enterprise Value is ₹6,133 Mil.
Bafna Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹207 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bafna Pharmaceuticals (NSE:BAFNAPH) has a EV-to-EBITDA of 29.62 as of Jul. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bafna Pharmaceuticals. This is 81% above median its historical median of 16.33. According to the industry distribution chart, Bafna Pharmaceuticals ranks #600 out of 742 companies in the Drug Manufacturers industry, placing it in the top 80.9%.
Is Bafna Pharmaceuticals' EV-to-EBITDA too high?
Bafna Pharmaceuticals' current EV-to-EBITDA of 29.62 is 81% above median its 10-year median of 16.33. The Drug Manufacturers industry median EV-to-EBITDA is 12.98. Bafna Pharmaceuticals' value of 29.62 is 128.2% above this industry median. Based on the distribution chart, Bafna Pharmaceuticals ranks #600 out of 742 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bafna Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bafna Pharmaceuticals ranks #600 out of 742 companies for EV-to-EBITDA. This places Bafna Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 12.98. Bafna Pharmaceuticals' value of 29.62 is 128.2% above this benchmark. While the company's 10-year median is 16.33 vs. the industry median of 12.98, Bafna Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.98, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bafna Pharmaceuticals's current EV-to-EBITDA of 29.62 is 128.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bafna Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bafna Pharmaceuticals's current EV-to-EBITDA is 29.62, which is 81% above median its own 10-year median of 16.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹91.24, compared to a current price of ₹238.15 — trading 161% above its estimated fair value. The current EV-to-EBITDA is 29.62, which is 81% above median its 10-year median of 16.33 and 128.2% above the Drug Manufacturers industry median of 12.98. Bafna Pharmaceuticals' overall GF Score™ is 60/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current EV-to-EBITDA is 29.62 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?
Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹238.15 is trading 161% above its estimated GF Value™ of ₹91.24.
GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:BAFNAPH:
EV-to-EBITDA: 29.62 (81% above median its 10-year median of 16.33)
GF Value™: ₹91.24 vs. price of ₹238.15 (161% above fair value)
Industry Position: 128.2% above the Drug Manufacturers median (#600 of 742)
No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
60GF Score
Get the complete analysis for NSE:BAFNAPH
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BAFNAPH has been successfully added to your 
